West Pharma HR chief logs stock awards, tax withholding

West Pharmaceutical Services senior vice president and chief HR officer Annette F. Favorite reported multiple equity transactions.

Rhea-AI Filing Summary

West Pharmaceutical Services senior vice president and chief HR officer Annette F. Favorite reported multiple equity transactions. On February 17, 2026, she acquired 441.957 shares of common stock through a grant or award and had 150.443 shares withheld to cover tax obligations. On February 18, 2026, she exercised 135.491 restricted stock units, converting them into the same number of common shares, with 35.757 shares withheld for taxes at prices of $243.1900 and $248.2600 per share, respectively. After these direct transactions, she held 17,374.4904 common shares directly and 4,962.0000 shares indirectly through a Non-Qualified Deferred Compensation Plan. Footnotes state that performance stock units from the 2023-2025 period vested and that restricted stock units convert into common stock on a one-for-one basis.

Insider Trade Summary

135.491 shares exercised/converted

Exercise 6 txns

Insider Favorite Annette F

Role Sr. VP & Chief HR Officer

Type	Security	Shares	Price	Value
Exercise	Rst. Stock Unit	135.491	$0.00	$0.00
Exercise	Common Stock	135.491	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	35.757	$248.26	$9K
Grant/Award	Common Stock	441.957	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	150.443	$243.19	$37K
holding	Common Stock	--	--	--

Holdings After Transaction: Rst. Stock Unit — 408.486 contracts (Direct); Common Stock — 17,374.4904 shares (Direct); Common Stock — 4,962 shares (Indirect, Non-Qualified Deferred Compensation Plan)

Footnotes (3)

1. F1. These shares result from performance stock units (PSUs) which vested at the end of the respective 2023-2025 PSU performance period and were payable on the transaction date shown.
2. F2. Restricted stock units convert into common stock on a one-for-one basis.
3. F3. On February 18, 2025, the reporting person was granted 542 restricted stock units, vesting in four equal annual installments (plus dividend equivalents).

FAQ

What insider transactions did WST executive Annette Favorite report?

Annette F. Favorite reported equity grants, derivative exercises, and tax-withholding disposals. She received 441.957 common shares, exercised 135.491 restricted stock units into common stock, and had 186.200 total shares withheld to satisfy tax liabilities tied to these awards.

Did the WST insider Form 4 show any open-market stock sales?

The filing shows no open-market sales. Dispositions, coded "F," reflect shares withheld to pay exercise-price or tax liabilities, not discretionary selling. These tax-withholding transactions reduced the net shares issued from equity awards but do not represent market sales by the executive.

How many WST shares does Annette Favorite hold after these transactions?

After the reported transactions, Annette F. Favorite directly holds 17,374.4904 shares of West Pharmaceutical common stock. She also has 4,962.0000 shares reported as indirect ownership through a Non-Qualified Deferred Compensation Plan, reflecting deferred equity-based compensation arrangements.

What types of equity awards were involved in the WST insider filing?

The filing involves performance stock units and restricted stock units. Footnotes note PSUs that vested for the 2023–2025 performance period and restricted stock units that convert into common stock on a one-for-one basis when they vest or are otherwise payable.

What do the tax-withholding transactions mean in the WST Form 4?

Tax-withholding transactions, coded "F," indicate shares withheld to cover exercise price or tax liabilities from equity awards. For Annette Favorite, 150.443 and 35.757 shares of common stock were withheld at specified prices, lowering her net shares received from the vested awards.

When did the reported WST insider equity transactions occur?

The transactions occurred on February 17 and February 18, 2026. On February 17, 2026, she received a grant and had shares withheld for taxes, and on February 18, 2026, she exercised restricted stock units with additional tax-withholding share disposals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/19/2026 - 06:58 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Favorite Annette F

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PA 19341

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr. VP & Chief HR Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		A		441.957(1)	A	$0	17,425.1994	D
Common Stock	02/17/2026		F		150.443	D	$243.19	17,274.7564	D
Common Stock	02/18/2026		M		135.491	A	(2)	17,410.2474	D
Common Stock	02/18/2026		F		35.757	D	$248.26	17,374.4904	D
Common Stock								4,962	I	Non-Qualified Deferred Compensation Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Rst. Stock Unit	(2)	02/18/2026		M			135.491	(3)	(3)	Common Stock	135.491	$0	408.486	D

Explanation of Responses:

1. These shares result from performance stock units (PSUs) which vested at the end of the respective 2023-2025 PSU performance period and were payable on the transaction date shown.

2. Restricted stock units convert into common stock on a one-for-one basis.

3. On February 18, 2025, the reporting person was granted 542 restricted stock units, vesting in four equal annual installments (plus dividend equivalents).

	/s/ Louis Lalli, as an agent for Annette Favorite	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.